RNAi gets boost with Roche acquisition of Mirus Bio

07/22/2008 | Reuters

Roche Holding purchased Mirus Bio Corp. in a $125 million deal that grants it access to the U.S. firm's gene-silencing technology. The acquisition brings the Swiss drugmaker "closer to creating fully enabled RNAi therapeutics," a Roche official said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC